4 recruiting, 1 completed, 1 unknown. 6 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Recruiting 4, Completed 1, Unknown 1 |
| Phase 2 | 2 | Recruiting 1, Unknown 1 |
Follow Neuroendocrine Cancer: new trials by email Literature Review of Neuroendocrine Cancer trials Research Report on Neuroendocrine Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Armored CAR T Cells in People With Cancer DLL3-SAVVYZ-IL18 CAR T cell - Neuroendocrine Cancer, Small Cell Lung Cancer | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 16 | 2026-08-28 | 2026-10-22 |
| TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors TLN-499, Venetoclax - Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer | Phase 1 | Recruiting | Treeline Biosciences, Inc. | 120 | 2026-08-05 | 2026-10-01 |
| Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors BL-M14D1 - Small Cell Lung Cancer Metastatic or Locally Advanced, Neuroendocrine Cancer | Phase 1 | Recruiting | SystImmune Inc. | 120 | 2025-04-28 | 2026-10-30 |
| Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer ZG006 - Small Cell Lung Cancer, Neuroendocrine Cancer | Phase 1 / Phase 2 | Recruiting | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 265 | 2024-09-02 | 2026-10-19 |
| 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography. - Neuroendocrine, Neuroendocrine Tumor | Phase 1 / Phase 2 | Unknown | Ochsner Health System | 250 | 2014-03-01 | 2014-01-17 |
| Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. PSMA/PRAME - Ovarian, Melanoma | Phase 1 | Completed | Mannkind Corporation | 12 | 2007-02-01 | 2010-08-03 |
Carcinoma, Neuroendocrine (6) · Small Cell Lung Carcinoma (4) · Adenoma, Islet Cell (1) · Anus Neoplasms (1) · Apudoma (1) · Biliary Tract Neoplasms (1) · Bone Neoplasms (1) · Breast Neoplasms (1) · Carcinoid Tumor (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Gallbladder Neoplasms (1) · Liver Neoplasms (1) · Melanoma (1) · Mesothelioma (1)
Adenocarcinoma (6) · Carcinoma (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms, Germ Cell and Embryonal (6) · Neoplasms, Glandular and Epithelial (6) · Neoplasms, Nerve Tissue (6) · Neuroectodermal Tumors (6) · Neoplasms by Site (5) · Neuroendocrine Tumors (5) · Bronchial Neoplasms (4) · Carcinoma, Bronchogenic (4) · Lung Diseases (4) · Lung Neoplasms (4) · Respiratory Tract Diseases (4)
venetoclax (1)
Mannkind Corporation (1) · Memorial Sloan Kettering Cancer Center (1) · Ochsner Health System (1) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (1) · SystImmune Inc. (1) · Treeline Biosciences, Inc. (1)
United States (4) · Australia (1) · China (1) · Georgia (1) · Ukraine (1)
Adam Schoenfeld, MD (1) · Jason Wu (1) · Junliang Cai (1) · Padma Yerramilli-Rao, MB BS, PhD (1)
R01CA303470 (1)